HR20031 FDC

HR20031 FDC is a fixed-dose combination (FDC) tablet developed to combine the active pharmaceutical ingredients SHR3824, SP2086, and metformin extended-release (XR) into a single oral dosage form. The drug is being evaluated for its bioequivalence compared to the co-administration of separate tablets of SHR3824, SP2086, and metformin XR. The primary aim is to simplify therapy by reducing pill burden and potentially improving adherence in patients who require these medications together. The specific mechanisms of action depend on the individual components: - SHR3824 and SP2086 are investigational agents; their precise pharmacological targets are not specified in available sources. - Metformin XR is a well-established antihyperglycemic agent that decreases hepatic glucose production and improves insulin sensitivity. The developer or sponsor associated with clinical studies involving HR20031 FDC has not been explicitly named in public records[1][6].

Other names

retagliptin phosphate瑞格列汀瑞泽唐